1991
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaCo-trimoxazole prophylaxisComplete response rateDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1976
Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.
Young R, DeVita V. Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine. National Cancer Institute Monograph 1976, 43: 193-200. PMID: 1087955.Peer-Reviewed Original ResearchConceptsPyrimethamine-sulfadiazinePneumocystis pneumoniaPentamidine isethionateClinical trialsPneumocystis carinii pneumoniaManagement of patientsSeverely ill patientsRandomized clinical trialsCarinii pneumoniaLocal toxicityRegimensIll patientsPatientsComplete recoveryPneumoniaPneumocystisIsethionateComparative toxicityTrialsPentamidineToxicity
1969
Pneumocystis carinii Pneumonia — Successful Diagnosis and Treatment of Two Patients with Associated Malignant Processes
DeVita V, Emmer M, Levine A, Jacobs B, Berard C. Pneumocystis carinii Pneumonia — Successful Diagnosis and Treatment of Two Patients with Associated Malignant Processes. New England Journal Of Medicine 1969, 280: 287-291. PMID: 5303991, DOI: 10.1056/nejm196902062800602.Peer-Reviewed Original ResearchConceptsNeedle biopsyMalignant processPentamidine isethionatePneumocystis carinii pneumoniaProper clinical settingPotential renal toxicityRenal functionAdequate therapyCarinii pneumoniaRenal toxicityPneumocystis infectionTubular disordersTherapeutic efficacyClinical settingFurther experiencePatientsBiopsyIsethionateTherapyInfectionDiagnosisValid assessmentPneumoniaPhysiciansDose